MedTrace Logo

The Research of Standard Diagnosis and Treatment for Severe HSP in Children

NCT02540720 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-02-26

No results posted yet for this study

Summary

This study is performed to evaluate the efficacy and safety of various measures in the treatment of severe HSP in children.

Conditions

  • Henoch-Schoenlein Purpura

Interventions

DRUG

Dexamethasone

DRUG

Gamma globulin

PROCEDURE

Hemoperfusion

Sponsors & Collaborators

  • Nanjing Children's Hospital

    lead OTHER

Principal Investigators

  • Aihua Zhang, M.D. · Department of Nephrology, Nanjing children's hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02540720 on ClinicalTrials.gov